Lloyd A. Rowland Jr., J.D.
Net Worth
Last updated:
What is Lloyd A. Rowland Jr., J.D. net worth?
The estimated net worth of Mr. Lloyd A. Rowland Jr., J.D. is at least $3,720,142 as of 19 Mar 2024. He owns shares worth $235,468 as insider, has earned $35,754 from insider trading and has received compensation worth at least $3,448,920 in CytomX Therapeutics, Inc..
What is the salary of Lloyd A. Rowland Jr., J.D.?
Mr. Lloyd A. Rowland Jr., J.D. salary is $574,820 per year as Senior Vice President, Gen. Counsel, Chief Compliance Officer & Sec. in CytomX Therapeutics, Inc..
How old is Lloyd A. Rowland Jr., J.D.?
Mr. Lloyd A. Rowland Jr., J.D. is 68 years old, born in 1957.
What stocks does Lloyd A. Rowland Jr., J.D. currently own?
As insider, Mr. Lloyd A. Rowland Jr., J.D. owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| CytomX Therapeutics, Inc. (CTMX) | Senior Vice President, Gen. Counsel, Chief Compliance Officer & Sec. | 117,728 | $2 | $235,468 |
What does CytomX Therapeutics, Inc. do?
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors. It also develops CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, as well as CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.
Lloyd A. Rowland Jr., J.D. insider trading
CytomX Therapeutics, Inc.
Mr. Lloyd A. Rowland Jr., J.D. has made 5 insider trades between 2019-2024, according to the Form 4 filled with the SEC. Most recently he sold 5,268 units of CTMX stock worth $10,989 on 19 Mar 2024.
The largest trade he's ever made was exercising 11,250 units of CTMX stock on 17 Dec 2023. As of 19 Mar 2024 he still owns at least 117,728 units of CTMX stock.
CytomX Therapeutics key executives
CytomX Therapeutics, Inc. executives and other stock owners filed with the SEC:
- Dr. Alison L. Hannah M.D. (64) Senior Vice President & Chief Medical Officer
- Dr. Amy C. Peterson M.D. (58) Executive Vice President & Chief Devel. Officer
- Dr. Sean A. McCarthy D.Phil., DPHIL (58) Chairman, Chief Executive Officer & Pres
- Mr. Carlos Campoy (60) Senior Vice President & Chief Financial Officer
- Mr. Frederick W. Gluck (90) Co-Founder & Independent Director
- Mr. Lloyd A. Rowland Jr., J.D. (68) Senior Vice President, Gen. Counsel, Chief Compliance Officer & Sec.